Market revenue in 2023 | USD 105.0 million |
Market revenue in 2030 | USD 155.1 million |
Growth rate | 5.7% (CAGR from 2023 to 2030) |
Largest segment | Inhaled |
Fastest growing segment | Other Allergens |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Inhaled, Drug, Other Allergens, Food |
Key market players worldwide | Rohm Co Ltd, Thermo Fisher Scientific Inc, PerkinElmer, BioMerieux SA, Siemens Healthineers AG ADR, Omega Healthcare Investors Inc, Danaher Corp, Alcon Inc, AbbVie Inc, Sanofi SA, Allergy Therapeutics PLC, Pfizer Inc, Teva Pharmaceutical Industries Ltd, GSK PLC, Sun Pharmaceutical Industries, Roche Holding AG, Merck & Co Inc, Astellas Pharma Inc, Epigenomics AG |
Inhaled was the largest segment with a revenue share of 49.52% in 2023. Horizon Databook has segmented the Sweden allergy diagnostics and therapeutics market based on inhaled, drug, other allergens, food covering the revenue growth of each sub-segment from 2018 to 2030.
Sweden’s allergy diagnostics and therapeutics market is projected to witness lucrative growth over the forecast period due rising prevalence of allergies and continuous developments by companies operating in the market.
Growing advancements in the healthcare sector, rising government initiatives to spread awareness about treatments related to allergies, and increasing investments in R&D sector are further expected to positively impact the market.
Sweden has major clinics and healthcare settings that provide proper treatment. Moreover, significant reimbursement policies propel the market growth in the country. Major players in the region include Danaher, Sanofi, and GSK.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account